Granting Waiver for Cancer Treatment Does Not Affect Safety, Efficacy Outcomes
By Elana Gotkine HealthDay Reporter
MONDAY, July 8, 2024 -- In a trial involving patients with therapy-refractory cancer treated with approved targeted or immunotherapies, matched to their tumor molecular profile but outside their registered indications, those for whom a waiver was granted had similar serious adverse event rates and clinical benefit rates as those who did not receive a waiver, according to a study published online June 27 in Clinical Cancer Research.
Jade M. van Berge Henegouwen, from Erasmus Medical Center in Rotterdam, Netherlands, and colleagues examined the impact of protocol waivers on treatment safety and efficacy in a multicenter, nonrandomized clinical basket trial treating patients with therapy-refractory cancer with molecularly targeted and immunotherapies outside their registered indications. All waivers granted were reviewed, analyzed in terms of safety and efficacy outcome, and compared to outcomes for patients who did not receive a waiver. Protocol waivers were granted for 82 of 1,019 eligible patients (8 percent) between Sept. 1, 2016, and Sept. 1, 2021.
The researchers found that 45 percent of waivers were granted for general or drug-related eligibility criteria; other categories included out-of-window testing, treatment exceptions, and testing exceptions. Patients who did and did not receive a waiver had a similar serious adverse event rate (39 versus 41 percent). The clinical benefit (objective response or stable disease ≥16 weeks) rate was 40 versus 33 percent for patients with versus without a waiver.
"The current data advocate that 'old' unnecessarily strict safety criteria should, where possible, be eliminated when setting-up new molecularly driven trials," the authors write.
The trial was funded by multiple pharmaceutical companies.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2024
Read this next
Health Care Expenditure Expected to Top GDP Growth 2024 to 2033
THURSDAY, July 3, 2025 -- The annual growth in national health spending is expected to be faster than average gross domestic product (GDP) growth during 2024 to 2033, according to...
Considerable Variation Seen in Commercial Pricing for Surgery Services
THURSDAY, July 3, 2025 -- Commercial pricing varies considerably for general surgery services, with facility prices exhibiting greater variability, according to a research letter...
Urinary Metal Levels Tied to Increased Risk for Later Heart Failure
THURSDAY, July 3, 2025 -- There are consistent associations between elevated urinary metal levels and increased heart failure risk over time across geographically diverse cohorts...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.